Your browser doesn't support javascript.
loading
OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma.
Thiebaud, Julio Alvarenga; Ravi, Vinod; Litwin, Samuel; Schuetze, Scott M; Movva, Sujana; Agulnik, Mark; Kraft, Andrew S; Tetzlaff, Eric D; Somaiah, Neeta; von Mehren, Margaret.
Afiliación
  • Thiebaud JA; Department of Hematology Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
  • Ravi V; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Litwin S; Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
  • Schuetze SM; Department of Medical Oncology, University of Michigan, Ann Arbor, Michigan, USA.
  • Movva S; Department of Hematology Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
  • Agulnik M; Department of Medical Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Kraft AS; Univeristy of Arizona Cancer Center, Tucson, Arizona, USA.
  • Tetzlaff ED; Department of Hematology Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
  • Somaiah N; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • von Mehren M; Department of Hematology Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Cancer ; 128(19): 3516-3522, 2022 10 01.
Article en En | MEDLINE | ID: mdl-35942596

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hemangiosarcoma Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hemangiosarcoma Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos